Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02871778 · ClinicalTrials.gov registry record · Phase 2
Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia
A Phase 2 study, sponsored by Parion Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 123
- Enrollment target
NCT02871778: Completed Phase 2 study, sponsored by Parion Sciences.
NCT02871778 is a Phase 2 study that has completed, run by Parion Sciences. The registered enrollment target is 123 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02871778, a Phase 2 study, has completed, sponsored by Parion Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 123 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of treatment with VX-371 with and without ivacaftor, and the effect of VX-371 with and without ivacaftor on quality of life (QOL) in subjects with primary ciliary dyskinesia (PCD).
Primary Outcome
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs included abnormal clinically significant findings for spirometry, clinical laboratory parameters, standard 12-lead electrocardiograms (ECGs), vital signs and pulse oximetry examinations. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitali
Interventions
- DRUG Ivacaftor
- DRUG Hypertonic Saline
- DRUG VX-371 + HS
- DRUG VX-371
- DRUG Placebo (0.17% saline)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2016-08 |
| Est. Completion | 2018-11-20 |
| Phase | Phase 2 |
What the finished NCT02871778 record still lists
NCT02871778 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 5 interventions - of which Ivacaftor is the first listed.
NCT02871778 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02871778 about?
NCT02871778 is a clinical study titled "Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia". To evaluate the safety and efficacy of treatment with VX-371 with and without ivacaftor, and the effect of VX-371 with and without ivacaftor on quality of life (QOL) in subjects with primary ciliary dyskinesia (PCD).
What is the current status of trial NCT02871778?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2016-08. Estimated completion is 2018-11-20.
What interventions are being tested in trial NCT02871778?
The interventions under investigation include: Ivacaftor (DRUG), Hypertonic Saline (DRUG), VX-371 + HS (DRUG), VX-371 (DRUG), Placebo (0.17% saline) (DRUG).
Who is sponsoring clinical trial NCT02871778?
This trial is sponsored by Parion Sciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02871778's enrollment target sits among peer trials
123 564th of 2000 higher than 1,436 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05285891 · 123 participants · Phase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- NCT05334368 · 123 participants · Phase 3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- NCT06088355 · 123 participants · NA
Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease
- NCT06111131 · 123 participants · NA
Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia